Form 4: Amicus Therapeutics Executive Samantha Prout Reports Stock Transactions

Samantha Prout, Chief Accounting Officer of Amicus Therapeutics, reports acquisition and disposal of company stock on February 11, 2025.

Summary

• On February 11, 2025, Samantha Prout, Chief Accounting Officer of Amicus Therapeutics, acquired 27,416 shares of common stock at $0.
• These shares were granted for the achievement of the 2022 PRSUs as determined by the Board of Directors.
• On the same day, Prout disposed of 13,500 shares of common stock at a price of $9.57.
• Following these transactions, Prout directly owns 109,441 shares of Amicus Therapeutics common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard disclosure of stock transactions. The acquisition of shares due to PRSU achievement is mildly positive, while the disposal is mildly negative, balancing out overall.

Positives

• The acquisition of shares indicates confidence in the company's performance, as the shares were granted for achieving performance-related stock units (PRSUs).

Negatives

• The disposal of 13,500 shares could be interpreted negatively, although it may be for personal financial management.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which can be useful for investors assessing management's sentiment and potential future performance.

Stakeholder Impact

• Shareholders may interpret the transactions as a reflection of management's confidence or need for liquidity.

Key Dates